Administrative & Regulatory

Administrative agencies and changes in the area of regulatory law, are two areas of law which are regularly covered in the news media. And, because these areas of law change frequently, it is important to have the latest news which is available. The National Law Review covers the latest administrative and regulatory actions as they unfold. From appointment of new Administrative law judges (ALJs), to the appointment of the Officer of Management and Budget office in Mick Mulvaney, the National Law Review covers this, and other agency and regulatory news as it unfolds.

New regulations in tax-law, rulemaking decisions, the Securities and Exchange Commission (SEC), and the latest news in regulatory agendas, are reported on daily on NLR’s website. The adjudication and enforcement of regulatory agendas, new appointments to government offices and agencies, and news from the federal and state-level, is updated on the National Law Review daily. Readers can find information about new legislation, law-making, changes in government agencies, the appointment of new directors, and litigation involving administrative and regulatory news as it unfolds.

Anything encompassing new government regulations will also be found under the administrative and regulatory law section on The National Law Review. Regulations made by government agencies via the powers appointed to them by statutes or the Constitution are highly covered topics on the National Law Review as well. For visitors who want the latest information on the new administration which is heading the CFPB, to reading about new state regulations where they live, will find such topics covered on NLR.

Because news is unfolding on a regular basis, visitors want to read about the latest topics, areas of concern, and rulemaking which might affect them in the future. The National Law Review adds new content on a daily basis, meaning visitors will always have up-to-date legal analysis on regulations that may impact their business.

 

For hourly updates on the latest in legal, legislation, government regulation, and corporate law news, be sure to follow the National Law Review Twitter feed, and sign up for complimentary e-news bulletins.

 

Custom text Title Sort descending Organization
Jul
19
2022
PFAS TRI Reporting Expanded By EPA CMBG3 Law
Jan
25
2022
PFAS TRI Reporting Expanded By EPA To 179 PFAS CMBG3 Law
Jan
9
2023
PFAS TRI Reporting Expanded By EPA- January 2023 CMBG3 Law
May
28
2023
PFAS under REACH — A Conversation with Jane S. Vergnes, Ph.D. [Podcast] Bergeson & Campbell, P.C.
Dec
5
2019
PFAS Update: EPA Progress Under PFAS Action Plan Robinson & Cole LLP
Sep
28
2021
PFAS Wastewater Discharge Regulations Take Step Forward CMBG3 Law
Apr
4
2023
PFAS Watch: Proposed New Drinking Water Limits and Likely Impacts Foley & Lardner LLP
Aug
11
2020
PFAS Water Cleanup…Have You Bought Yourself a Multi-Million Dollar Superfund Issue? CMBG3 Law
Apr
1
2024
PFAS – What to Know Now, and What to Expect Bergeson & Campbell, P.C.
Oct
1
2020
PFAS — What You Need to Know in Transactions Van Ness Feldman LLP
May
21
2021
PFAS, PFAS All Around: What's Next? [Video] Mintz
Jan
23
2023
PFAS-Containing Consumer Products Under Attack in California ArentFox Schiff LLP
Sep
25
2019
PFAS: What Is It and Why Should You Care? von Briesen & Roper, s.c.
Oct
31
2019
PFAS: Why the hysteria? Godfrey & Kahn S.C.
Mar
24
2023
Pfizer Expands Cancer Drug Portfolio with $43 Billion Biotech Acquisition MoginRubin
Jan
23
2013
Pfizer FCPA Settlement Emphasizes the Importance of Robust Compliance Programs for the Healthcare Industry Sheppard, Mullin, Richter & Hampton LLP
Nov
30
2021
Pfizer is Reportedly Lobbying Against Key Amendments to the False Claims Act Kohn, Kohn & Colapinto
Mar
22
2024
PFOF Verbot McDermott Will & Emery
Sep
1
2012
Pharmaceutical Industry Executives Face Enforcement Risks Under The Responsible Corporate Officer Doctrine Faegre Drinker
Sep
20
2022
Pharmaceutical Manufacturer Pays $7.9 Million to Resolve Allegations that it Caused the Submission of Over-the-Counter Drugs to Medicare Part D Mintz
Mar
16
2021
Pharmaceutical Mergers: U.S. Antitrust Agencies Join Global Working Group Cadwalader, Wickersham & Taft LLP
Dec
6
2012
Pharmaceutical Patent Transfers Subject to the Hart Scott Rodino Act (HSR Act): Increased Review Raises Importance of Valuation Greenberg Traurig, LLP
Oct
29
2020
Pharmaceutical Price Reduction Approaches Giordano, Halleran & Ciesla, P.C.
Oct
11
2014
Pharmaceutical Research and Manufacturers of America (PhRMA) Filed Suit Today Seeking to Invalidate the 340B Orphan Drug Exclusion Interpretative Rule Covington & Burling LLP
Jun
27
2012
Pharmaceutical Sales Representatives Are Exempt Under the FLSA ArentFox Schiff LLP
Jun
25
2012
Pharmaceutical Sales Representatives Qualify For The “Outside Sales” Exemption To The Fair Labor Standards Act, Supreme Court Says Neal, Gerber & Eisenberg LLP
Aug
29
2014
Pharmacies Avoid False Claims Act Suit: Fox Rx Inc. v. Omnicare Inc. et al. Covington & Burling LLP
Jun
6
2023
Pharmacy Benefit Managers are on the Federal Government’s Radar: Senate, House, and Agency Proposals Seek to Increase PBM Oversight – Part 1 Mintz
Nov
13
2020
Pharmacy Compliance: What Do You Need to Know? Oberheiden P.C.
Oct
19
2020
Phase 3 of NJEDA Small Businesses Emergency Assistance Grant Program Stark & Stark
Feb
2
2013
Phase 3 of the America Invents Act: New Patent Laws Take Effect on March 16, 2013 Greenberg Traurig, LLP
Jun
11
2010
Phase II of the FDA’s Transparency Initiative: The Transparency Task Force Releases Draft Recommendations on FDA’s Public Disclosure Policies Foley Hoag LLP
Jul
3
2020
Phase III of Massachusetts Reopening Starts July 6 Jackson Lewis P.C.
Apr
3
2019
Phase One of Premium Processing for FY 2020 Cap-Subject H-1B Petitions Begins May 20 Greenberg Traurig, LLP
Aug
17
2012
Phase-out of Form I-94 around the corner Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins